Biotron Limited Stock Performance
| BITRF Stock | USD 0.01 0.00 0.00% |
The firm shows a Beta (market volatility) of 1.88, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biotron will likely underperform. At this point, Biotron Limited has a negative expected return of -0.97%. Please make sure to confirm Biotron's variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Biotron Limited performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Biotron Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 4.2 M |
Biotron |
Biotron Relative Risk vs. Return Landscape
If you would invest 3.63 in Biotron Limited on September 1, 2024 and sell it today you would lose (2.38) from holding Biotron Limited or give up 65.56% of portfolio value over 90 days. Biotron Limited is currently producing negative expected returns and takes up 9.5411% volatility of returns over 90 trading days. Put another way, 84% of traded pink sheets are less volatile than Biotron, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biotron Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotron's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biotron Limited, and traders can use it to determine the average amount a Biotron's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1019
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BITRF |
Estimated Market Risk
| 9.54 actual daily | 84 84% of assets are less volatile |
Expected Return
| -0.97 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Biotron is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotron by adding Biotron to a well-diversified portfolio.
Biotron Fundamentals Growth
Biotron Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biotron, and Biotron fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotron Pink Sheet performance.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.56 | |||
| Profit Margin | (1.78) % | |||
| Operating Margin | (1.78) % | |||
| Current Valuation | 15.31 M | |||
| Shares Outstanding | 901.94 M | |||
| Price To Earning | (3.04) X | |||
| Price To Book | 23.61 X | |||
| Price To Sales | 11.17 X | |||
| Revenue | 1.56 M | |||
| EBITDA | (2.73 M) | |||
| Cash And Equivalents | 1.74 M | |||
| Total Debt | 77.24 K | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (2.44 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 1.91 M | |||
| Retained Earnings | (37 M) | |||
| Current Asset | 3 M | |||
About Biotron Performance
By analyzing Biotron's fundamental ratios, stakeholders can gain valuable insights into Biotron's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biotron has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biotron has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia. Biotron operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Biotron Limited performance evaluation
Checking the ongoing alerts about Biotron for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biotron Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotron Limited generated a negative expected return over the last 90 days | |
| Biotron Limited has high historical volatility and very poor performance | |
| Biotron Limited has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 1.56 M. Net Loss for the year was (2.78 M) with profit before overhead, payroll, taxes, and interest of 1.56 M. | |
| Biotron Limited has accumulated about 1.74 M in cash with (2.44 M) of positive cash flow from operations. | |
| Roughly 14.0% of the company shares are held by company insiders |
- Analyzing Biotron's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotron's stock is overvalued or undervalued compared to its peers.
- Examining Biotron's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotron's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotron's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotron's pink sheet. These opinions can provide insight into Biotron's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biotron Pink Sheet analysis
When running Biotron's price analysis, check to measure Biotron's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotron is operating at the current time. Most of Biotron's value examination focuses on studying past and present price action to predict the probability of Biotron's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotron's price. Additionally, you may evaluate how the addition of Biotron to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |